National Guideline Clearinghouse | Somatostatin analogues for the management of neuroendocrine tumours.

National Guideline Clearinghouse | Somatostatin analogues for the management of neuroendocrine tumours.

CancerControl Alberta

• Somatostatin analogues for the management of neuroendocrine tumours. This updates a previously published guideline summary.

Guideline Title

Somatostatin analogues for the management of neuroendocrine tumours.

Bibliographic Source(s)

Alberta Provincial Endocrine Tumour Team. Somatostatin analogues for the management of neuroendocrine tumours. Edmonton (AB): CancerControl Alberta; 2015 Mar. 19 p. (Clinical practice guideline; no. ENDO-003).  [50 references]

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Alberta Provincial Endocrine Tumour Team. Octreotide for the management of neuroendocrine tumours. Edmonton (Alberta): CancerControl Alberta; 2013 Nov. 16 p. (Clinical practice guideline; no. ENDO-003). [46 references]

This guideline meets NGC's 2013 (revised) inclusion criteria.